These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18991685)

  • 1. Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.
    Porcellini E; Davis EJ; Chiappelli M; Ianni E; Di Stefano G; Forti P; Ravaglia G; Licastro F
    Curr Pharm Des; 2008; 14(26):2659-64. PubMed ID: 18991685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
    DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI
    Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma alpha1-antichymotrypsin in Alzheimer's disease; relationships with APOE genotypes.
    Scacchi R; Ruggeri M; Gambina G; Martini MC; Ferrari G; Corbo RM
    Neurobiol Aging; 2001; 22(3):413-6. PubMed ID: 11378247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease.
    Licastro F; Chiappelli M; Grimaldi LM; Morgan K; Kalsheker N; Calabrese E; Ritchie A; Porcellini E; Salani G; Franceschi M; Canal N
    Neurobiol Aging; 2005 Apr; 26(4):449-53. PubMed ID: 15653173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies.
    Nielsen HM; Minthon L; Londos E; Blennow K; Miranda E; Perez J; Crowther DC; Lomas DA; Janciauskiene SM
    Neurology; 2007 Oct; 69(16):1569-79. PubMed ID: 17761554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.
    Pirttila T; Mehta PD; Frey H; Wisniewski HM
    Neurobiol Aging; 1994; 15(3):313-7. PubMed ID: 7936055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.
    Hsiung GY; Sadovnick AD; Feldman H
    CMAJ; 2004 Oct; 171(8):863-7. PubMed ID: 15477624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype.
    Licastro F; Masliah E; Pedrini S; Thal LJ
    Dement Geriatr Cogn Disord; 2000; 11(1):25-8. PubMed ID: 10629358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.
    Patra K; Soosaipillai A; Sando SB; Lauridsen C; Berge G; Møller I; Grøntvedt GR; Bråthen G; Begcevic I; Moussaud S; Minthon L; Hansson O; Diamandis EP; White LR; Nielsen HM
    Alzheimers Res Ther; 2018 Jan; 10(1):9. PubMed ID: 29378650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers.
    Yoshiiwa A; Kamino K; Yamamoto H; Kobayashi T; Imagawa M; Nonomura Y; Yoneda H; Sakai T; Nishiwaki Y; Sato N; Rakugi H; Miki T; Ogihara T
    Ann Neurol; 1997 Jul; 42(1):115-7. PubMed ID: 9225693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein ɛ4 is Associated with Dementia and Cognitive Impairment Predominantly Due to Alzheimer's Disease and Not with Vascular Cognitive Impairment: A Singapore-Based Cohort.
    Chai YL; Yeo HK; Wang J; Hilal S; Ikram MK; Venketasubramanian N; Wong BS; Chen CL
    J Alzheimers Dis; 2016; 51(4):1111-8. PubMed ID: 26923016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment.
    Chiappelli M; Borroni B; Archetti S; Calabrese E; Corsi MM; Franceschi M; Padovani A; Licastro F
    Rejuvenation Res; 2006; 9(4):485-93. PubMed ID: 17105389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
    Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
    J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.